Johnson & Johnson vs Roche: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Johnson & Johnson and Roche side by side

1. 1886Johnson & Johnson

   Johnson & Johnson Founded

   Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found the company in New Brunswick, New Jersey, with 14 employees, to mass-produce sterile surgical dressings after Robert was inspired by antiseptic pioneer Joseph Lister's 1885 warnings about i…

2. 1896Roche

   F. Hoffmann-La Roche Founded in Basel

   Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.

3. 1898Roche

   Commercial Breakthrough with Sirolin

   Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.

4. 1920Johnson & Johnson

   Band-Aid Brand Adhesive Bandages Introduced

   J&J introduces the first mass-produced adhesive bandage, sold under the Band-Aid brand starting in 1921; it becomes one of the most recognized consumer-health brands in the world before J&J later spins its consumer division out as Kenvue in 2023.

5. 1934Roche

   First Industrial Synthesis of Vitamin C

   Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.

6. 1943Johnson & Johnson

   Robert Wood Johnson II Writes 'Our Credo'

   Chairman Robert Wood Johnson II authors 'Our Credo,' a one-page statement ranking the company's responsibilities to customers, employees, communities, and shareholders in that order; it remains J&J's official governing philosophy and was later cited as the bas…

7. 1944Johnson & Johnson

   J&J Goes Public

   Johnson & Johnson lists publicly, becoming an independent, market-traded company as it expands into a diversified healthcare business under Chairman Robert Wood Johnson II.

8. 1963Roche

   Launch of Valium (Diazepam)

   Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.

9. 1968Roche

   Establishment of Roche Diagnostics

   Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.

10. 1982Johnson & Johnson

    Tylenol Cyanide Poisonings and Nationwide Recall

    After seven people in the Chicago area die from cyanide-laced Extra-Strength Tylenol capsules, J&J issues a nationwide recall of 31 million bottles within a week -- far beyond what investigators said was necessary -- citing Our Credo's customer-safety priority…

11. 2008Roche

    Severin Schwan becomes CEO

    Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.

12. 2009Roche

    Full Acquisition of Genentech for $46.8 Billion

    Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.

13. 2012Johnson & Johnson

    Alex Gorsky Becomes CEO

    Gorsky succeeds William Weldon as CEO amid a period of manufacturing-quality recalls, and spends the next decade restoring J&J's operational reputation while expanding the pharmaceutical and MedTech businesses and developing a single-dose COVID-19 vaccine duri…

14. 2018Roche

    Foundation Medicine & Flatiron Health Acquisitions

    Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.

15. 2022Johnson & Johnson

    Joaquin Duato Becomes CEO

    Duato becomes CEO in January 2022, later adding the chairman title, and begins preparing the separation of J&J's consumer-health business from its medicine and device operations.

16. 2023Johnson & Johnson

    Kenvue Separation

    J&J completes the spinoff of its consumer-health business (Band-Aid, Tylenol, Listerine, Neutrogena) as the standalone public company Kenvue, narrowing J&J around its higher-margin Innovative Medicine and MedTech segments.

17. 2023Roche

    Acquired Telavant

    F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.

18. 2025Johnson & Johnson

    FY2025 Sales of $94.193B

    Johnson & Johnson reports $94.193 billion in sales and $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year.

19. 2025Johnson & Johnson

    Orthopaedics Separation Announced

    In October 2025 J&J announced plans to separate its orthopaedics business as a standalone company operating as DePuy Synthes, targeting completion in 2027.

20. 2025Roche

    Group Sales Reach CHF 61.5 Billion

    Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.

21. 2026Johnson & Johnson

    Proposed Talc Resolution and Raised Guidance

    J&J raised 2026 sales guidance to about $101.1 billion after Q2 sales of $25.31 billion, and on July 27, 2026 proposed an estimated $5.5 billion resolution of remaining ovarian talc claims.

Acquisitions

Questions about Johnson & Johnson vs Roche